Products
BDR is a niche player in today's international and domestic arena.
specialization in early identification, development
BDR is credited with specialization in early identification, development and introduction of new and fourth generation medicines in various life threatening segments. Our task is made easier by undying and spirited support we receive from cross section of our employees - from high end professionals of over 30 years industry experience to young ones.
As BDR Pharma Group, we have facilities for API, Finished Dosage and Pellets across India and is also setting up plants overseas to meet the global demand for our niche products. Currently, our existing Oral Oncology Formulation and Oncology API units, accredited by EU-GMP, are commercially manufacturing products like Tamoxifen, Sorafenib, Lapatinib, Abiraterone, Enzalutamide, Everolimus, Dasatinib, Lenvatinib, Axitinib, and Ibrutinib. From the same facility, we plan to soon start manufacturing Bosutinib and many more such critical products. Also, within our Group, we have an EU-GMP-approved Oncology injectable unit dedicated to producing several products including Degarelix Acetate, Clofarabine, Albumin-bound Paclitaxel and Eribulin, among others.
We are probably India's fastest growing generic pharmaceutical company dealing in specialty products.
View ProductsWe Are Credited With Manufacturing And Exporting Unique And New APIs.
we are trend setters in critical and life threatening segments
We have world class state-of-the-art Oncology Oral Dosage finished dosage and API facilities located within the same campus. Both have accreditations from WHO GMP, EU GMP and poised for more audits in the near future.
We have an impeccable track record for early identification, development and development of molecules with strategic partners across the globe. We are driven by the necessity to make available high end products at affordable prices to ailing patients. This is our unwritten commitment to suffering community, worldwide.
Disclaimer : Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at the buyer's risk. Products currently covered by valid patents in India are offered for R&D purpose in accordance with Section 107(A) of the Patents Act, 1970.
Our Offering
API
Nice segments API R&D and manufacturing facilities with Global Accreditations following cGMP standards with utmost care of quality.
Formulations
Front runner in terms of formulation development of molecules, technology and dosage forms with competitive edge and commercial viability that are manufactured in units having Global cGMP certification.
Pellets
Development of sustained and modified pellets using innovative drug delivery technologies with latest manufacturing technologies is our forte. Emphasis is laid upon new and niche product development.
a range of pharmaceutical products
